H.C. Wainwright analyst Patrick Trucchio believes the FDA approval of Ionis Pharmaceuticals’ (IONS) Tryngolza, an oligonucleotide, for the treatment of familial chylomicronemia syndrome, has positive read-through to Arrowhead’s (ARWR) plozasiran. Based on the “compelling” Phase 3 trial data generated from Arrowhead’s plozasiran, an RNA interference therapeutic targeting apolipoprotein C-III in familial chylomicronemia syndrome, plozasiran should also be approved by the second half of 2025 with a broad label, the analyst tells investors in a research note. Furthermore, with “best-in-class” characteristics on efficacy, quarterly dosing, and side effect profile, H.C. Wainwright believes plozasiran, if approved, is well positioned to become standard-of-care in familial chylomicronemia syndrome. The firm reiterates a Buy rating on the shares with an $80 price target.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARWR:
- Leadership Transition at Arrowhead Pharmaceuticals’ Board
- Arrowhead announces interim results from ARO-CFB study
- Arrowhead price target raised to $80 from $60 at H.C. Wainwright
- Arrowhead requests regulatory clearance to initiate ARO-ALK7 trial
- Sarepta price target lowered to $75 from $80 at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
